| Identification | Back Directory | [Name]
3-Quinolinecarboxylic acid, 7-[(7S)-7-aMino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-4-oxo-, hydrate | [CAS]
163253-37-0 | [Synonyms]
Sitafloxacin (Monohydrate)
3-Quinolinecarboxylic acid, 7-[(7S)-7-aMino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-4-oxo-, hydrate | [Molecular Formula]
C19H20ClF2N3O4 | [MOL File]
163253-37-0.mol | [Molecular Weight]
427.83 |
| Hazard Information | Back Directory | [Uses]
Sitafloxacin (DU6859a) monohydrate is a potent, orally active fluoroquinolone antibiotic. Sitafloxacin monohydrate shows antichlamydial activity and antibacterial activities against a broad range of gram-positive and gram-negative bacteria, including anaerobic bacteria, as well as against atypical pathogens. Sitafloxacin monohydrate can be used for the research of respiratory tract infection and urinary tract infection[1][2]. | [in vivo]
Sitafloxacin (DU6859a; 12.5-100 mg/kg; i.g.; daily for 4 weeks; BALB/c female mice) monohydrate has antibacterial activity. M. ulcerans cells could be isolated from the inoculated footpads and there was no evidence of footpad swelling[2]. | Animal Model: | BALB/c female mice[2] | | Dosage: | 12.5, 25, 50 and 100 mg/kg | | Administration: | Oral gavage; daily, for 4 weeks | | Result: | Inhibits the growth of Mycobacterium ulcerans and the M. ulcerans cells. |
| [IC 50]
Quinolone | [References]
[1] Okumura R, et al. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008 Jul;62(1):98-104. DOI:10.1093/jac/dkn136
[2] Dhople AM, et al. Activities of sitafloxacin (DU-6859a), either singly or in combination with rifampin, against Mycobacterium ulcerans infection in mice. J Chemother. 2003 Feb;15(1):47-52. DOI:10.1179/joc.2003.15.1.47 |
|
|